The following information is simply informational. Its intent is not to replace the advice of a veterinarian nor to assist you in making a diagnosis of your pet. Please consult with your own veterinary physician for confirmation of any diagnosis. Your pet’s life may depend on it.
These tumors (also called mastocytomas, mast cell sarcomas) are the most frequently recognized malignant or potentially malignant neoplasms of dogs. In addition, leukemic and visceral forms can occur. A viral etiology has been speculated but remains controversial. These tumors may occur in dogs of any age (average 8-10 yr). They may occur anywhere on the body surface as well as in internal organs, but the limbs (especially the posterior upper thigh), ventral abdomen, and thorax are the most common sites; ~10% are multicentric. Many breeds appear to be predisposed, especially Boxers and Pugs (in which tumors are often multiple), Rhodesian Ridgebacks, and Boston Terriers. The tumors vary markedly in size, and clinical appearance alone cannot establish a diagnosis.
Most commonly, they appear as raised, nodular masses that on palpation may be soft to solid. Although they often seem encapsulated, mast cell tumors in dogs are seldom discrete. Rather, they consist of a highly cellular center surrounded peripherally by a “halo” of smaller numbers of mast cells that palpate as normal skin. Dogs can also develop clinical signs associated with the release of vasoactive products from the malignant mast cells. Most common is gastroduodenal ulceration that may be present in up to 25% of cases.
This is Peanut, a Boston Terrier presenting with what his vets have called, “the worse case” of mast cell tumors they have ever seen.
This is Cucumber, a beagle mix, with Mast Cell in it’s advanced stages. Hers began as a small lump on the left side of her muzzle. As you can see in the photos above, the cancer has caused deformity of her face, listing her nose to the right and pushing her left eye from proper seating in it’s socket. The open area by her mouth was caused by scratching most likely due to the discomfort it caused her.
The behavior of mast cell tumors is variable in that some are rapidly fatal and others are benign. One in eleven cases will appear as multiple nodules involving all the skin. I like to refer to mast cell tumors as cancer and “tricksters” because they can’t be trusted to behave according to their classification. Most pathologists will report them as Grade II, which means they don’t know how they’ll behave. The Grade III cases are almost always fatal. Some will appear rapidly on the face feet or axilla and resemble insect bites.
One can distinguish mast cell tumors from benign fatty tumors with cytology, the examination of cells from a fine-needle aspirate. It is excellent practice to perform cytology before surgery. I like to use New Methylene Blue stain on all my cytology specimens. The dark blue storage granules of mast cells are easy to see under microscopic examination of the stained aspirate. Early diagnosis and aggressive treatment are most effective against this common cancer.
Cytologic evaluation of Wright’s-stained, fine-needle aspirates or impression smears can be used to establish the diagnosis of mast cell tumors in dogs. However, cytology is not a substitute for histopathology—only the latter has been correlated with prognosis. Two systems of histopathologic grading have been defined, and to avoid confusion, it is essential to know which of the two systems is being used.
Although there is believed to be a benign variant of canine mast cell tumor, there is no clinical or microscopical means of identifying it. In addition, small mast cell tumors may remain quiescent for long periods before becoming aggressive. Thus, all should be treated as at least potential malignancies.
Clinical Trial for Canine Mast Cell Tumor Patients
Trial eligibility criteria include:
- measurable recurrent cutaneous mast cell tumor
- no more than one regional lymph node involved
- no visceral (liver, spleen, intestinal) metastases
- limited past use of chemotherapy and/or radiation therapy IS acceptable
Trial Support/Funding Includes:
- diagnostic tests (to define eligibility and for follow up)
- oral treatment agent
- follow up examinations
Eligible patients will have the opportunity to receive the investigational compound under closely monitored conditions while participating in the study (limitations apply). Dogs will receive the oral medication over a 6-week initial phase. Follow-up will include weekly examinations during the initial phase and then re-check examinations every 6 weeks pending response.
Participating Animal Cancer Institute Network trial sites:
Animal Cancer Institute at Friendship Hospital
Beltway Oncology and Internal Medicine
Atlantic Veterinary Internal Medicine
Regional Veterinary Referral Associates
Southpaws Veterinary Referral Center
VCA – Veterinary Referral Associates
For more information please contact the Animal Cancer Institute (202-363-7300) or see their website at www.animalcancerinstitiute.com.
Clinical Trial Results:
1. Prostaglandins Leukot Essent Fatty Acids. 2003 May;Effects of fatty acids on mediators of mass cells in culture. Gueck T, Seidel A, Fuhrmann H. Faculty of Veterinary Medicine, Institute of Physiological Chemistry, University of Leipzig,
An den Tierkliniken 1, D-04103, Leipzig, Germany. email@example.com
The objective of this study was to investigate the effects of alpha-linolenic acid (18:3n-3) and linoleic acid (18:2n-6) on the fatty acid composition and the activity and release of mast cell mediators in the canine mastocytoma cell line C2. Cells were cultured in Dulbecco’s modified Eagle’s medium mixed with 50% Ham’s F12 (containing linoleic acid 0.14 micro M). The basic medium (DEH) was supplemented with 0.14 micro M alpha-linolenic acid. 14.0 micro M alpha-linolenic acid (DEH-n-3) or 14.0 micro M linoleic acid (DEH-n-6) was added. Eight days after culturing of C2 in DEH-n-3 we measured elevated levels of n-3 fatty acids up to 22:3. The tryptase activity and the stimulated PGE2 production and histamine release were reduced. In contrast, after culturing of C2 in DEH-n-6 we determined elevated levels of n-6 fatty acids up to 20:3, increased tryptase activity and stimulated histamine release. Thus 18:3n-3 has anti-inflammatory effects in cultured canine mastocytoma cells.
PMID: 12711248 [PubMed - in process]
2. Vet Dermatol. 2002 Dec;13(6):301-5.
Influence of vitamin E on mast cell mediator release.
Gueck T, Aschenbach JR, Fuhrmann H.
Institute of Physiological Chemistry, Faculty of Veterinary Medicine, University of Leipzig, An den Tierkliniken 1, 04103 Leipzig, Germany. firstname.lastname@example.org
We investigated the influence of vitamin E on mediator activity and release in a canine mastocytoma cell line (C2) as a model for canine atopic dermatitis. Cells were incubated without and with vitamin E (100 microm) for 24 h. The histamine and prostaglandin D2 (PGD2) release as well as the chymase and tryptase activity were measured. To stimulate the PGD2 and histamine release, cells were incubated with the wasp venom peptide mastoparan (50 microm) for 30 or 45 min. Nonstimulated as well as mastoparan-stimulated histamine and PGD2 release was reduced significantly in vitamin E-treated cells. The activity of chymase tended to decrease, but the tryptase activity of C2 cells was not influenced by vitamin E. These results indicate that vitamin E decreased the production and release of inflammatory mediators in C2 cells, suggesting that vitamin E might have a possible beneficial effect in inflammatory diseases.
PMID: 12464062 [PubMed - indexed for MEDLINE]
LINKS FOR ADDITIONAL INFORMATION ON MAST CELL TUMORS
Merck Veterinary Manual 8th edition.
Many thanks and acknowledgment to Dr. Alice Villalobos, Editor-in-Cheif of the American Association of Human Animal Bond Veterinarians; Animal Oncology Consultation Service Coast Pet Clinic of Hermosa Beach, Inc. for enthusiatically granting us permission to use the above information. To read more about the wonderful work Dr. Villalobos has done in the field of animal oncology click here.
Published for MEDLINE, National Library of Medicine
Any information on this site is published under the “fair use” act. If you are the author, researcher or contributor to any of the information contained herein and would prefer not to have your information included on the site, please contact us and it will be removed immediately.